EDIT250117P20000
- 0.00
- 0.000.00%
Editas Medicine Newsroom
BofA Securities Maintains Editas Medicine(EDIT.US) With Sell Rating, Announces Target Price $1
Editas Medicine: Strategic Ambitions and Cautious Optimism in Gene-Editing Advancements
Wells Fargo Maintains Editas Medicine(EDIT.US) With Hold Rating, Cuts Target Price to $3
TD Cowen Maintains Editas Medicine(EDIT.US) With Buy Rating
Editas Medicine (EDIT) Receives a Buy From TD Cowen
Express News | Editas Medicine Inc - to Submit at Least One Ind/Cta by 2027
Express News | Editas Medicine Highlights New in Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-Year Strategic Priorities
Press Release: Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities
Gene Editing Stocks Drop as Intellia Announces Layoffs
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In?
Clear Street Initiates Editas Medicine(EDIT.US) With Buy Rating, Announces Target Price $4
Evercore Maintains Editas Medicine(EDIT.US) With Buy Rating, Cuts Target Price to $5
Evercore ISI Group Maintains Outperform on Editas Medicine, Lowers Price Target to $5
JP Morgan Downgrades Editas Medicine to Underweight
J.P. Morgan Downgrades Editas Medicine(EDIT.US) to Sell Rating
Analysts Offer Insights on Healthcare Companies: Affimed (AFMD), Editas Medicine (EDIT) and Trevi Therapeutics (TRVI)
Express News | Editas Medicine Inc : JP Morgan Cuts to Underweight From Neutral
Morgan Stanley Maintains Editas Medicine(EDIT.US) With Hold Rating
A Quick Look at Today's Ratings for Editas Medicine(EDIT.US), With a Forecast Between $3 to $3